Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
IPO Year:
Exchange: NYSE
Website: questdiagnostics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/30/2026 | $210.00 | Equal Weight → Overweight | Barclays |
| 8/25/2025 | $194.00 | Outperform → Neutral | Robert W. Baird |
| 4/2/2025 | $195.00 | Buy | Redburn Atlantic |
| 3/4/2025 | $185.00 | Buy → Neutral | Citigroup |
| 1/6/2025 | $169.00 → $174.00 | Market Perform → Outperform | Leerink Partners |
| 12/17/2024 | $145.00 → $172.00 | Equal-Weight → Overweight | Morgan Stanley |
| 12/10/2024 | $175.00 → $185.00 | Buy | Jefferies |
| 10/23/2024 | $157.00 → $182.00 | Neutral → Outperform | Robert W. Baird |
| 8/28/2024 | $165.00 | In-line | Evercore ISI |
| 7/10/2024 | $145.00 → $165.00 | Neutral → Buy | Citigroup |
10-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)
8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)
8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)
8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)
10-Q - QUEST DIAGNOSTICS INC (0001022079) (Filer)
144 - QUEST DIAGNOSTICS INC (0001022079) (Subject)
144 - QUEST DIAGNOSTICS INC (0001022079) (Subject)
144 - QUEST DIAGNOSTICS INC (0001022079) (Subject)
SCHEDULE 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)
10-Q - QUEST DIAGNOSTICS INC (0001022079) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Barclays upgraded Quest Diagnostics from Equal Weight to Overweight and set a new price target of $210.00
Robert W. Baird downgraded Quest Diagnostics from Outperform to Neutral and set a new price target of $194.00
Redburn Atlantic initiated coverage of Quest Diagnostics with a rating of Buy and set a new price target of $195.00
Citigroup downgraded Quest Diagnostics from Buy to Neutral and set a new price target of $185.00
Leerink Partners upgraded Quest Diagnostics from Market Perform to Outperform and set a new price target of $174.00 from $169.00 previously
Morgan Stanley upgraded Quest Diagnostics from Equal-Weight to Overweight and set a new price target of $172.00 from $145.00 previously
Jefferies resumed coverage of Quest Diagnostics with a rating of Buy and set a new price target of $185.00 from $175.00 previously
Robert W. Baird upgraded Quest Diagnostics from Neutral to Outperform and set a new price target of $182.00 from $157.00 previously
Evercore ISI resumed coverage of Quest Diagnostics with a rating of In-line and set a new price target of $165.00
Citigroup upgraded Quest Diagnostics from Neutral to Buy and set a new price target of $165.00 from $145.00 previously
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
Fastest customizable press release news feed in the world
Veteran M&A and transformation leader from Danaher and Patheon joins the Quest Diagnostics executive teamSECAUCUS, N.J., Feb. 26, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, today announced that Benjamin Beauvalot, a highly accomplished leader with more than two decades of experience in business strategy and transformation, including mergers and acquisitions (M&A), has joined the company as senior vice president, chief strategy and M&A officer. In this role, Mr. Beauvalot is responsible for developing the company's gr
SECAUCUS, N.J., Feb. 25, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President & Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during the Leerink 2026 Global Healthcare Conference in Miami on Wednesday, March 11, 2026, at 8:00 a.m. Eastern Time. The Fireside Chat and Q&A session will be webcast live during the conference on the company's investor relations page, which can be accessed at ir.QuestDiagn
Fourth quarter revenues of $2.81 billion, up 7.1% from 2024Fourth quarter reported diluted earnings per share ("EPS") of $2.18, up 11.8% from 2024; and adjusted diluted EPS of $2.42, up 8.5% from 2024Full year revenues of $11.04 billion, up 11.8% from 2024Full year reported diluted EPS of $8.75, up 13.8% from 2024; and adjusted diluted EPS of $9.85, up 10.3% from 2024 Full year cash from operations of $1.89 billionFull year 2026 revenues expected to be between $11.70 billion and $11.82 billion Full year 2026 reported diluted EPS expected to be between $9.45 and $9.65; and adjusted diluted EPS expected to be between $10.50 and $10.70SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagno
SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced that the Company's Board of Directors has authorized a 7.5% increase in its quarterly cash dividend to $0.86 per share from $0.80 per share. The increase is effective with the dividend payable on April 20, 2026 to shareholders of record of Quest Diagnostics common stock on April 6, 2026. With the increase, the annual cash dividend will be $3.44 per share. Additionally, the Board of Directors has increased the Company's
New test as sensitive as next-generation sequencing, and provides five-day specimen stability to support nationwide testing SECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel blood test that uses advanced flow cytometry methods to assess measurable residual disease (MRD) in patients with the blood cancer myeloma (also called multiple myeloma). Called Quest Flow Cytometry MRD for Myeloma, the new test provides comparable sensitivity as next-generation sequencing methods in detecting residual myeloma*, but at a fraction of the cost, supporting better care and outcomes.
SECAUCUS, N.J., Jan. 21, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, today announced that it has been named to the Fortune® magazine 2026 World's Most Admired Companies™ list, for the 12th consecutive year. "Quest's recognition as one of the world's most admired companies reflects the commitment of our 55,000 colleagues to living our purpose every day: working together to create a healthier world, one life at a time," said Jim Davis, Chairman, CEO and President. "We are proud to again be named among this elite list
Jennifer Erickson succeeds longtime CEO David Dexter following more than 26 years of service PHOENIX, Jan. 15, 2026 /PRNewswire/ -- Sonora Quest Laboratories, together with its parent company Laboratory Sciences of Arizona (LSA), is pleased to announce the appointment of Jennifer Erickson as Chief Executive Officer-Elect. Erickson will take over from David Dexter, who is retiring this March after more than 26 years of leadership. Dexter joined Sonora Quest and LSA as president and CEO in 1999, where under his leadership, the company has grown tremendously, serving as the marke
Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham
SECAUCUS, N.J., Jan. 8, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 10, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast
SECAUCUS, N.J., Jan. 6, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that data will be shared on circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing during two poster presentations at the 2026 ASCO Gastrointestinal Cancers Symposium, being held January 8-10, 2026 in San Francisco, CA., and online. The studies evaluate the use of ctDNA in colorectal cancer using the Haystack MRD® test from Quest Diagnostics. Details of the poster presentations are as follows: Title: Reproducibility an
Live Leadership Updates
Jennifer Erickson succeeds longtime CEO David Dexter following more than 26 years of service PHOENIX, Jan. 15, 2026 /PRNewswire/ -- Sonora Quest Laboratories, together with its parent company Laboratory Sciences of Arizona (LSA), is pleased to announce the appointment of Jennifer Erickson as Chief Executive Officer-Elect. Erickson will take over from David Dexter, who is retiring this March after more than 26 years of leadership. Dexter joined Sonora Quest and LSA as president and CEO in 1999, where under his leadership, the company has grown tremendously, serving as the marke
Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham
Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J., Jan. 17, 2024 /PRNewswire/ -- Fitbit and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced a collaboration to study the potential of wearable devices to improve metabolic health, which influences risk of developing several diseases, including diabetes and heart disease. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair beh
SECAUCUS, N.J., March 3, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors elected James E. Davis, the company's Chief Executive Officer and President, to serve in the additional position of Chairman of the Board of Directors, effective April 1, 2023. "The Board carefully considered our governance structure and determined that combining the roles of Chairman and CEO under Jim Davis's leadership is in the best interest of shareholders to successfully continue to execute
JERSEY, Channel Islands, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Ali Kiboro as the Company's Chief Financial Officer (CFO). Mr. Kiboro will assume the responsibilities of CFO on November 1st, 2021, replacing Mr. Peter Buhler who will support the Company during the transitional phase, as needed, before leaving Quotient Limited at year-end. "I am delighted to welcome Ali to the Executive team at this exciting time in our Company's evolution. He brings over 20 years of experience in global finance and has been a key driver of operational excellence in a career spanning healthcare services and manufacturing. I w
WNS (Holdings) Limited (NYSE:WNS), a leading provider of global Business Process Management (BPM) solutions, today announced the appointment of Timothy L. Main to the company's Board of Directors effective June 1, 2021. Tim has spent his entire career in a B2B services/outsourcing environment, including more than 25 years with Jabil, Inc. (NYSE:JBL), a leading provider of manufacturing services with a global operational footprint. At Jabil, Tim worked his way from a Production Control Manager position to eventually serve as President, Chief Executive Officer, and Chairman of the Board. During his 13-year tenure as Chief Executive Officer of Jabil, he led the company's transformation and gro
Live finance-specific insights
Fourth quarter revenues of $2.81 billion, up 7.1% from 2024Fourth quarter reported diluted earnings per share ("EPS") of $2.18, up 11.8% from 2024; and adjusted diluted EPS of $2.42, up 8.5% from 2024Full year revenues of $11.04 billion, up 11.8% from 2024Full year reported diluted EPS of $8.75, up 13.8% from 2024; and adjusted diluted EPS of $9.85, up 10.3% from 2024 Full year cash from operations of $1.89 billionFull year 2026 revenues expected to be between $11.70 billion and $11.82 billion Full year 2026 reported diluted EPS expected to be between $9.45 and $9.65; and adjusted diluted EPS expected to be between $10.50 and $10.70SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagno
SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced that the Company's Board of Directors has authorized a 7.5% increase in its quarterly cash dividend to $0.86 per share from $0.80 per share. The increase is effective with the dividend payable on April 20, 2026 to shareholders of record of Quest Diagnostics common stock on April 6, 2026. With the increase, the annual cash dividend will be $3.44 per share. Additionally, the Board of Directors has increased the Company's
SECAUCUS, N.J., Jan. 8, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 10, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast
SECAUCUS, N.J., Nov. 11, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on January 28, 2026 to shareholders of record of Quest Diagnostics common stock on January 13, 2026. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to t
Third quarter revenues of $2.82 billion, up 13.1% from 2024Third quarter reported diluted earnings per share ("EPS") of $2.16, up 8.5% from 2024; and adjusted diluted EPS of $2.60, up 13.0% from 2024Year-to-date cash provided by operations of $1.4 billion, up 63.1% from 2024Full year 2025 reported diluted EPS now expected to be between $8.58 and $8.66; and adjusted diluted EPS is expected to be between $9.76 and $9.84SECAUCUS, N.J., Oct. 21, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the third quarter ended September 30, 2025.
SECAUCUS, N.J., Sept. 25, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report third quarter 2025 financial results on Tuesday, October 21, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted
SECAUCUS, N.J., Aug. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on October 20, 2025 to shareholders of record of Quest Diagnostics common stock on October 3, 2025. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to ta
Second quarter revenues of $2.76 billion, up 15.2% from 2024Second quarter reported diluted earnings per share ("EPS") of $2.47, up 21.7% from 2024; and adjusted diluted EPS of $2.62, up 11.5% from 2024Year-to-date cash provided by operations of $858 million, up 67.1% from 2024Full year 2025 reported diluted EPS now expected to be between $8.60 and $8.80; and adjusted diluted EPS is expected to be between $9.63 and $9.83SECAUCUS, N.J., July 22, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2025.
SECAUCUS, N.J., June 23, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report second quarter 2025 financial results on Tuesday, July 22, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.Q
SECAUCUS, N.J., May 14, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on July 21, 2025 to shareholders of record of Quest Diagnostics common stock on July 7, 2025. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take acti
This live feed shows all institutional transactions in real time.
SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)
SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)
SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)
SC 13G - QUEST DIAGNOSTICS INC (0001022079) (Subject)
SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)
SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)